Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks? : Market Research Report

Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks?

Published: Apr. 27, 2007 - 17 Pages

The price of this report has been reduced due to its age. The original price was $2,025 for PDF.

Executive Summary: Strategic Considerations; Stakeholder Implications
Introduction
Coronary Heart Disease and Stent Use: Coronary Heart Disease; Treatment for Coronary Heart Disease; The Use of Cardiac Stents
The Drug-Eluting Stent Market: Market Leaders; The Battle for Guidant
Concerns Arise over Drug-Eluting Stents
Emerging Innovations in Drug-Eluting Stents: Medtronic’s Endeavor Stent; Abbott’s Xience/Boston Scientifi c’s Promus; Conor Medsystems’ Costar; Biosensors’ BioMatrix
The Outlook for the Drug-Eluting Stent Market: Safety Concerns Create Commercial Opportunities; The Emergence of Competitive Pricing; Bioabsorbable Stents; Market Rebound
Tables: 1. Prevalence of Coronary Heart Disease and Acute Coronary Syndrome, 2006; 2. Emerging Drug-Eluting Stents
Figures: 1. Milestones in the Drug-Eluting Stent Market; 2. Stent Implantation, Restenosis, and Thrombosis; 3. Worldwide Sales of Taxus Versus Cypher

Abstract

A few years after their introduction in 2002, drug-eluting stents had all but replaced bare-metal stents in the treatment of coronary heart disease, capturing up to 90% of the market. Physicians favored the new stents primarily because of their ability to minimize the risk of restenosis associated with bare-metal stents. Recently, however, new safety concerns have begun to erode the market share of drug-eluting stents. The promise of next-generation drug-eluting stents that are beginning to emerge—including Medtronic’s Endeavor, expected to launch in the United States in late 2007, and Abbott’s Xience, currently in clinical trials in the United States and Japan—is likely to help the drug-eluting stent market rebound from its current low. However, lingering safety concerns and the possibility of competitive pricing may keep the market from achieving its earlier high.

Get the Answers You Need to Shape Your Strategy

The need to effectively compete with the next generation of drug-eluting stents has prompted the current market leaders—Johnson & Johnson and Boston Scientifi c—to acquire companies with next-generation stents in their pipelines. How do next-generation stents differ from currently available drug-eluting stents? Will the recent mergers of Boston Scientifi c and Guidant and Johnson & Johnson and Conor Medsystems help the market leaders to retain their market dominance?
Recent concerns that drug-eluting stents are associated with increased risk of late stent thrombosis arise from data on just two products—Boston Scientifi c’s Taxus stent and Cordis/Johnson & Johnson’s Cypher stent. What competitive opportunities does the potential for late stent thrombosis offer to manufacturers of other drug-eluting stents? How do current concerns about the risk of late stent thrombosis affect the outlook for Medtronic’s Endeavor stent, if it receives approval in the United States?
To acquire Guidant, Boston Scientifi c not only took on a heavy debt load, it also struck a deal with Abbott Laboratories that gave Abbott rights to Guidant’s Xience V DES platform. Was the decision to acquire Guidant a good strategic move for Boston Scientifi c? Will Boston Scientifi c’s privatelabel Xience stent, Promus, affect the company’s overall sales of drug-eluting stents?
Recent safety concerns about drug-eluting stents have dampened the early enthusiasm for this technology. How is the FDA likely to respond to the recent safety concerns about drug-eluting stents? Is the drug-eluting stent market likely to rebound from its recent fall?
In March 2007, Medtronic released two-year results from the largest and longest drug-eluting stent clinical trial program to date. What advantages does Medtronic’s Endeavor stent offer over existing drug-eluting stents? How is the availability of the Endeavor stent likely to affect the market share of the Taxus and Cypher stents?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Drug-Eluting Stents: Can the Market Rebound from Recent Setbacks?

Table of Contents

Abstract